Clarinex-D 24-hour approved
This article was originally published in The Tan Sheet
Executive Summary
FDA clears the Rx desloratadine 5 mg/pseudoephedrine sulfate 240 mg combination "for relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis (outdoor allergies), including nasal congestion, in patients 12 years of age and older," Schering-Plough announces March 4. The agency approved the extension following review of two randomized, parallel group clinical trials evaluating 2,852 subjects ages 12 to 78 over two weeks; 708 participants received Clarinex-D. "In both trials, the antihistaminic efficacy of Clarinex-D 24-Hour, when examining symptoms of allergic rhinitis excluding nasal congestion, was significantly greater than pseudoephedrine or Claritin 5 mg alone," Schering says. Availability of the non-sedating antihistamine tablets will coincide with the spring allergy season...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.